Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Si Hyoung Kim"'
Autor:
Si Hyoung Kim, Yun Kyung Cho, Ye-Jee Kim, Chang Hee Jung, Woo Je Lee, Joong-Yeol Park, Ji Hye Huh, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-11 (2022)
Abstract Background The atherogenic index of plasma (AIP) is composed of triglycerides and high-density lipoprotein cholesterol and is a novel marker for assessing the risk of atherogenicity and cardiometabolic health. An association between AIP and
Externí odkaz:
https://doaj.org/article/270245eff4824d8788d2c316b3533fb3
Autor:
Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, Sung-Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, Seong Jin Lee
Publikováno v:
Tumor Biology, Vol 39 (2017)
The effect of the dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with the heat shock protein 90 inhibitor NVP-AUY922 (AUY922) on survival of thyroid carcinoma cells was elucidated. The SW1736 and TPC-1 human thyroid carcinoma c
Externí odkaz:
https://doaj.org/article/d00b5da5e0644833b5bb3a524bdaf310
Autor:
Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, Sung-Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, Seong Jin Lee
Publikováno v:
Tumor Biology, Vol 39 (2017)
The influence of celastrol alone or in combination with paclitaxel on survival of anaplastic thyroid carcinoma cells was investigated. In 8505C and SW1736 cells, after treatment of celastrol, cell viability decreased, and cytotoxic activity increased
Externí odkaz:
https://doaj.org/article/5dbc2a3af4d84d58bf22facb793e131d
Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells
Autor:
Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, Sung-Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, Seong Jin Lee
Publikováno v:
Tumor Biology, Vol 39 (2017)
In this study, the combined effect of doxorubicin with cucurbitacin B on survival of anaplastic thyroid carcinoma cells was evaluated. For experiments, 8505C and CAL62 human anaplastic thyroid carcinoma cells were used. Cell viability, the percentage
Externí odkaz:
https://doaj.org/article/79dfa47339684cd48bf4ef9cce9aebd5
Autor:
Kwang-Seock Kim, Si Hyoung Kim, Chang-Nim Im, Kun Na, Moo-Yeal Lee, Jong Kook Park, Hyo-Jeong Kuh
Publikováno v:
Biochemical and Biophysical Research Communications. 647:30-36
Autor:
Moon Gi Choi, Yun Kyung Cho, Jun Goo Kang, Sung-Hee Ihm, Seong Jin Lee, Si Hyoung Kim, Ji Hye Huh
Publikováno v:
Anticancer research. 40(11)
BACKGROUND/AIM Heat shock protein 90 (HSP90) controls maturation of oncogenic client proteins of cancer cells, and thus we studied the effect of HSP 90 inhibitors on cell survival and survival-related mediators in thyroid carcinoma cells. MATERIALS A
Publikováno v:
Anticancer Research. 38:6339-6352
Background/aim The aim of this study was to evaluate the effect of evodiamine alone or in combination with chemotherapeutic agents on thyroid carcinoma cells. Materials and methods TPC-1 and SW1736 thyroid carcinoma cells were used. Cell viability, c
Publikováno v:
Endocrine. 65(1)
The impact of evodiamine in combination with histone deacetylase (HDAC) inhibitors on survival of thyroid carcinoma cells was identified. TPC-1 and SW1736 human thyroid carcinoma cells were used. After treatment with evodiamine and PXD101, cell viabi
Autor:
Si Hyoung Kim, Sung-Hee Ihm, Seong Jin Lee, Jun Goo Kang, Chul Sik Kim, Hyung Joon Yoo, Moon Gi Choi
Publikováno v:
Biochemical and Biophysical Research Communications. 455:363-370
We aimed to elucidate the effect of herbimycin A (HMA), a heat shock protein 90 inhibitor, on cell growth and epithelial-mesenchymal transition (EMT) in anaplastic thyroid carcinoma (ATC) cells. HMA inhibited cell growth and migration concomitantly w
Autor:
Jun Goo Kang, Hyung Joon Yoo, Si Hyoung Kim, Chul Sik Kim, Sung-Hee Ihm, Seong Jin Lee, Moon Gi Choi
Publikováno v:
Tumor Biology, Vol 39 (2017)
The effect of the dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with the heat shock protein 90 inhibitor NVP-AUY922 (AUY922) on survival of thyroid carcinoma cells was elucidated. The SW1736 and TPC-1 human thyroid carcinoma c